270 studies found for:    United States, Texas | United States, Texas | cook children's
Show Display Options
Rank Status Study
21 Enrolling by invitation Littlears Auditory Questionnaire: Validation Study in CI Children
Condition: Hearing Loss
Intervention:
22 Terminated Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
Conditions: Relapsed Acute Lymphoblastic Leukemia;   Relapsed Acute Myelogenous Leukemia
Intervention: Drug: GNKG168
23 Active, not recruiting Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Graft Versus Host Disease;   L1 Childhood Acute Lymphoblastic Leukemia;   L2 Childhood Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: thiotepa;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: methotrexate;   Drug: sirolimus;   Radiation: total body irradiation
24 Active, not recruiting Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: asparaginase;   Drug: dasatinib;   Drug: daunorubicin hydrochloride;   Drug: prednisone;   Drug: methylprednisolone;   Drug: methotrexate;   Drug: cytarabine;   Drug: etoposide;   Drug: ifosfamide;   Biological: filgrastim;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: pegaspargase;   Drug: dexamethasone;   Drug: mercaptopurine;   Radiation: radiation therapy;   Drug: hydrocortisone sodium succinate;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis
25 Recruiting Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Conditions: Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Stage I Wilms Tumor;   Stage II Wilms Tumor;   Stage III Wilms Tumor;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
Interventions: Drug: doxorubicin hydrochloride;   Procedure: therapeutic conventional surgery;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: carboplatin;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy
26 Completed Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Conditions: Childhood Hepatocellular Carcinoma;   Papillary Thyroid Cancer;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Liver Cancer;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Thyroid Cancer;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: sorafenib tosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
27 Active, not recruiting
Has Results
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Condition: Lymphoblastic Leukemia, Acute
Interventions: Drug: Prednisone, Dexamethasone, Vincristine, Daunorubicin;   Drug: Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase;   Drug: Methotrexate, Cyclophosphamide, Cytarabine, Etoposide;   Drug: Mercaptopurine, Imatinib;   Procedure: chemotherapy, intrathecal chemotherapy;   Procedure: steroid therapy, hematopoietic stem cell transplantation
28 Recruiting Safety and Efficacy Study of Daptomycin When Compared to Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis
Condition: Acute Hematogenous Osteomyelitis
Interventions: Drug: Daptomycin;   Drug: Vancomycin;   Drug: nafcillin
29 Recruiting Isotretinoin With or Without Monoclonal Antibody Ch14.18, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: isotretinoin;   Biological: sargramostim;   Biological: dinutuximab;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Other: pharmacological study
30 Recruiting International Pediatric Adrenocortical Tumor Registry
Condition: Adrenocortical Tumor
Intervention:
31 Active, not recruiting Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
Conditions: Adult Rhabdomyosarcoma;   Alveolar Childhood Rhabdomyosarcoma;   Embryonal Childhood Rhabdomyosarcoma;   Metastatic Childhood Soft Tissue Sarcoma;   Previously Untreated Childhood Rhabdomyosarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Biological: cixutumumab;   Drug: doxorubicin hydrochloride;   Drug: irinotecan hydrochloride;   Drug: liposomal vincristine sulfate;   Drug: ifosfamide;   Drug: etoposide;   Drug: cyclophosphamide;   Biological: dactinomycin;   Drug: temozolomide;   Other: laboratory biomarker analysis
32 Active, not recruiting Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
Conditions: Adult Rhabdomyosarcoma;   Alveolar Childhood Rhabdomyosarcoma;   Mixed Childhood Rhabdomyosarcoma;   Pleomorphic Childhood Rhabdomyosarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma
Interventions: Drug: vinorelbine tartrate;   Drug: cyclophosphamide;   Biological: bevacizumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis
33 Active, not recruiting Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
Condition: Recurrent Neuroblastoma
Interventions: Biological: hu14.18-IL2 fusion protein;   Drug: isotretinoin;   Biological: sargramostim;   Other: laboratory biomarker analysis
34 Completed Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Conditions: Childhood Hepatoblastoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: alisertib;   Other: pharmacological study;   Other: laboratory biomarker analysis
35 Active, not recruiting Fludarabine-based Conditioning for Severe Aplastic Anemia
Condition: Anemia, Aplastic
Intervention: Drug: Cyclophosphamide
36 Active, not recruiting Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
Conditions: Childhood Acute Basophilic Leukemia;   Childhood Acute Eosinophilic Leukemia;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: cytarabine;   Drug: thioguanine;   Drug: etoposide;   Other: laboratory biomarker analysis
37 Recruiting A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Condition: Medulloblastoma
Interventions: Radiation: Craniospinal Irradiation with boost to the primary tumor site;   Drug: Cyclophosphamide;   Drug: Cisplatin;   Drug: Vincristine;   Drug: Vismodegib;   Drug: Pemetrexed;   Drug: Gemcitabine;   Other: Aerobic Training;   Other: Neurocognitive Remediation
38 Active, not recruiting Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging
Conditions: Adrenocortical Carcinoma;   Localized Resectable Neuroblastoma;   Precancerous Condition
Interventions: Procedure: computed tomography;   Procedure: 3-Tesla magnetic resonance imaging;   Procedure: Abdominal Sonogram
39 Active, not recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Conditions: Childhood Acute Promyelocytic Leukemia (M3);   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: arsenic trioxide;   Drug: mitoxantrone hydrochloride;   Other: diagnostic laboratory biomarker analysis;   Drug: idarubicin;   Drug: tretinoin;   Drug: cytarabine;   Drug: mercaptopurine tablet;   Drug: methotrexate
40 Completed Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Condition: Protein C Deficiency
Intervention: Drug: Protein C Concentrate (Human) Vapor Heated

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years